Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06CAC
|
|||
| Drug Name |
Anidulafungin
|
|||
| Synonyms |
Ecalta; Eraxis; Anidulafungin [USAN:INN]; Ecalta (TN); Eraxis (TN); LY-303366; V-Echinocandin; VER-002
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Candidiasis [ICD-11: 1F23] | Approved | [1] | |
| Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Investigative | [2] | ||
| Therapeutic Class |
Antiviral Agents
|
|||
| Company |
Pfizer Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C58H73N7O17
|
|||
| Canonical SMILES |
CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC=C(C=C7)O)O)O)C(C)O)C)O)O)O
|
|||
| InChI |
1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1
|
|||
| InChIKey |
JHVAMHSQVVQIOT-MFAJLEFUSA-N
|
|||
| CAS Number |
CAS 166663-25-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10256118, 12014781, 14914844, 15264060, 46240216, 46505616, 49964787, 53131326, 57350924, 87351905, 113458539, 126666769, 134337837, 135653705, 137006424, 137428870, 142533035, 160687794, 160963709, 162172161, 162224777, 163366578, 164777757, 175266135, 179150043, 185973999, 203355939, 206711581, 223661184, 223715562, 226423880, 247516987, 251916118, 251917466, 252109699, 252214735
|
|||
| ChEBI ID |
CHEBI:55346
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | COVID-19 RNA-directed RNA polymerase (RdRp) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Suramin, Penciclovir and Anidulafungin bind nsp12, which governs the RNA-dependent-RNA polymerase activity of SARS-CoV-2, with higher interaction energy than Remdesivir, indicating potential in the treatment of Covid-19 infection. April.21.2020. Doi: 10.31219/osf.io/urxwh | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.